These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 8630291

  • 21. Absolute bioavailability studies of a new oral topotecan formulation in Chinese patients using UHPLC-MS/MS.
    Li N, Han X, Yang J, Gui L, Song Y, Du P, Shi Y.
    J Pharm Biomed Anal; 2013 Mar 25; 76():252-6. PubMed ID: 23354352
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function.
    Devriese LA, Witteveen PE, Mergui-Roelvink M, Smith DA, Lewis LD, Mendelson DS, Bang YJ, Chung HC, Dar MM, Huitema AD, Beijnen JH, Voest EE, Schellens JH.
    Br J Clin Pharmacol; 2015 Aug 25; 80(2):253-66. PubMed ID: 25677219
    [Abstract] [Full Text] [Related]

  • 24. Reduced albumin binding promotes the stability and activity of topotecan in human blood.
    Mi Z, Malak H, Burke TG.
    Biochemistry; 1995 Oct 24; 34(42):13722-8. PubMed ID: 7577964
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH, McCune JS, Lindley C, Faucette S, Shord S, Donahue A, Socinski MA, Stewart CF, Zamboni WC, Kirstein MN, Moore D.
    Cancer Invest; 2005 Oct 24; 23(6):511-9. PubMed ID: 16203659
    [Abstract] [Full Text] [Related]

  • 28. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Fields S, Von Hoff DD, Verweij J.
    Clin Cancer Res; 1998 May 24; 4(5):1153-8. PubMed ID: 9607572
    [Abstract] [Full Text] [Related]

  • 29. Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors.
    Sparreboom A, de Jonge MJ, Punt CJ, Nooter K, Loos WJ, Porro MG, Verweij J.
    Clin Cancer Res; 1998 Aug 24; 4(8):1915-9. PubMed ID: 9717819
    [Abstract] [Full Text] [Related]

  • 30. Limited sampling models for topotecan pharmacokinetics.
    van Warmerdam LJ, Verweij J, Rosing H, Schellens JH, Maes RA, Beijnen JH.
    Ann Oncol; 1994 Mar 24; 5(3):259-64. PubMed ID: 8186175
    [Abstract] [Full Text] [Related]

  • 31. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
    Gerrits CJ, Schellens JH, Burris H, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Von Hoff DD, Verweij J.
    Clin Cancer Res; 1999 Jan 24; 5(1):69-75. PubMed ID: 9918204
    [Abstract] [Full Text] [Related]

  • 32. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
    Rubin E, Wood V, Bharti A, Trites D, Lynch C, Hurwitz S, Bartel S, Levy S, Rosowsky A, Toppmeyer D.
    Clin Cancer Res; 1995 Mar 24; 1(3):269-76. PubMed ID: 9815982
    [Abstract] [Full Text] [Related]

  • 33. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.
    Baker SD, Heideman RL, Crom WR, Kuttesch JF, Gajjar A, Stewart CF.
    Cancer Chemother Pharmacol; 1996 Mar 24; 37(3):195-202. PubMed ID: 8529278
    [Abstract] [Full Text] [Related]

  • 34. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function.
    O'Reilly S, Rowinsky E, Slichenmyer W, Donehower RC, Forastiere A, Ettinger D, Chen TL, Sartorius S, Bowling K, Smith J, Brubaker A, Lubejko B, Ignacio V, Grochow LB.
    J Natl Cancer Inst; 1996 Jun 19; 88(12):817-24. PubMed ID: 8637048
    [Abstract] [Full Text] [Related]

  • 35. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
    Schiller JH, Kim K, Hutson P, DeVore R, Glick J, Stewart J, Johnson D.
    J Clin Oncol; 1996 Aug 19; 14(8):2345-52. PubMed ID: 8708727
    [Abstract] [Full Text] [Related]

  • 36. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates.
    Blaney SM, Cole DE, Balis FM, Godwin K, Poplack DG.
    Cancer Res; 1993 Feb 15; 53(4):725-7. PubMed ID: 8428353
    [Abstract] [Full Text] [Related]

  • 37. No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients.
    Zackrisson AL, Malmström H, Peterson C.
    Eur J Clin Pharmacol; 2002 May 15; 58(2):103-8. PubMed ID: 12012141
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.